文献速递银屑病与炎症性皮肤病湿疹皮炎与荨麻疹

银屑病生物制剂治疗中矛盾性湿疹的风险

Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
PubMed 文献 · JAMA Dermatol · 2024-01-01

结果显示,IL-23抑制剂相比TNF抑制剂与更低的矛盾性湿疹风险相关(HR 0.39;95%CI 0.19-0.81),年龄增长、女性、特应性皮炎或花粉症病史与风险升高相关,总体发生率较低。

要点

  • IL-23抑制剂治疗者的矛盾性湿疹风险显著低于TNF抑制剂(HR 0.39)。
  • 特应性皮炎病史者矛盾性湿疹风险显著升高(HR 12.40)。

核心结论

  • 在接受生物制剂治疗的银屑病患者中,矛盾性湿疹总体发生率较低,IL-23抑制剂使用者风险最低。
  • 年龄增长、女性、特应性皮炎或花粉症病史与矛盾性湿疹风险升高相关。

研究设计与样本

  • 前瞻性队列研究,使用英国和爱尔兰皮肤科生物制剂与免疫调节剂注册登记数据。
  • 暴露时间为从开始生物制剂治疗至矛盾性湿疹发生、停药、末次随访或死亡。

主要发现

  • 273次暴露(1%)与矛盾性湿疹相关。
  • 调整后发生率:IL-17抑制剂1.22/10万人年,TNF抑制剂0.94/10万人年,IL-12/23抑制剂0.80/10万人年,IL-23抑制剂0.56/10万人年。
  • 与TNF抑制剂相比,IL-23抑制剂与更低的矛盾性湿疹风险相关(HR 0.39;95%CI 0.19-0.81)。
  • IL-17抑制剂(HR 1.03;95%CI 0.74-1.42)和IL-12/23抑制剂(HR 0.87;95%CI 0.66-1.16)与矛盾性湿疹风险无显著关联。
  • 年龄增长(每岁HR 1.02;95%CI 1.01-1.03)、特应性皮炎病史(HR 12.40;95%CI 6.97-22.06)和花粉症病史(HR 3.78;95%CI 1.49-9.53)与风险升高相关;男性风险较低(HR 0.60;95%CI 0.45-0.78)。

关键数值与推荐

  • IL-23抑制剂相比TNF抑制剂,矛盾性湿疹风险HR 0.39(95%CI 0.19-0.81)。
  • 特应性皮炎病史者矛盾性湿疹风险HR 12.40(95%CI 6.97-22.06)。
  • 花粉症病史者HR 3.78(95%CI 1.49-9.53);男性HR 0.60(95%CI 0.45-0.78)。

临床怎么用

  • 选择生物制剂时可考虑IL-23抑制剂作为降低矛盾性湿疹风险的选择。
  • 对具有特应性皮炎或花粉症病史的银屑病患者,应加强矛盾性湿疹监测。

局限性

  • 研究结果需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Biologics used for plaque psoriasis have been reported to be associated with an atopic dermatitis (AD) phenotype, or paradoxical eczema, in some patients. The risk factors for this are unknown. OBJECTIVE: To explore risk of paradoxical eczema by biologic class and identify factors associated with paradoxical eczema. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study used data from the British Association of Dermatologists Biologics and Immunomodulators Register for adults treated with biologics for plaque psoriasis who were seen at multicenter dermatology clinics in the UK and Ireland. Included participants were registered and had 1 or more follow-up visits between September 2007 and December 2022. EXPOSURES: Duration of exposure to tumor necrosis factor (TNF) inhibitors, interleukin (IL) 17 inhibitors, IL-12/23 inhibitors, or IL-23 inhibitors until paradoxical eczema onset, treatment discontinuation, last follow-up, or death. MAIN OUTCOMES AND MEASURES: Incidence rates of paradoxical eczema, paradoxical eczema risk by biologic class, and the association of demographic and clinical variables with risk of paradoxical eczema were assessed using propensity score-weighted Cox proportional hazards regression models. RESULTS: Of 56 553 drug exposures considered, 24 997 from 13 699 participants were included. The 24 997 included exposures (median age, 46 years [IQR, 36-55 years]; 57% male) accrued a total exposure time of 81 441 patient-years. A total of 273 exposures (1%) were associated with paradoxical eczema. The adjusted incidence rates were 1.22 per 100 000 person-years for IL-17 inhibitors, 0.94 per 100 000 person-years for TNF inhibitors, 0.80 per 100 000 person-years for IL-12/23 inhibitors, and 0.56 per 100 000 person-years for IL-23 inhibitors. Compared with TNF inhibitors, IL-23 inhibitors were associated with a lower risk of paradoxical eczema (hazard ratio [HR], 0.39; 95% CI, 0.19-0.81), and there was no association of IL-17 inhibitors (HR, 1.03; 95% CI, 0.74-1.42) or IL-12/23 inhibitors (HR, 0.87; 95% CI, 0.66-1.16) with risk of paradoxical eczema. Increasing age (HR, 1.02 per year; 95% CI, 1.01-1.03) and history of AD (HR, 12.40; 95% CI, 6.97-22.06) or hay fever (HR, 3.78; 95% CI, 1.49-9.53) were associated with higher risk of paradoxical eczema. There was a lower risk in males (HR, 0.60; 95% CI, 0.45-0.78). CONCLUSIONS AND RELEVANCE: In this study, in biologic-treated patients with psoriasis, paradoxical eczema risk was lowest in patients receiving IL-23 inhibitors. Increasing age, female sex, and history of AD or hay fever were associated with higher risk of paradoxical eczema. The overall incidence of paradoxical eczema was low. Further study is needed to replicate these findings.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Al-Janabi A, Alabas OA, Yiu ZZN, et al. Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis. JAMA Dermatol. 2024. PMID: 38055239. doi:10.1001/jamadermatol.2023.4846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。